Jeffrey Browning

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1997126/publications.pdf

Version: 2024-02-01

84 papers	17,036 citations	34016 52 h-index	62479 80 g-index
84 all docs	84 docs citations	84 times ranked	14628 citing authors

#	Article	IF	Citations
1	Mice Transgenic for Baff Develop Lymphocytic Disorders along with Autoimmune Manifestations. Journal of Experimental Medicine, 1999, 190, 1697-1710.	4.2	1,347
2	BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth. Journal of Experimental Medicine, 1999, 189, 1747-1756.	4.2	1,213
3	A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature, 2000, 406, 309-314.	13.7	1,103
4	BAFFANDAPRIL: A Tutorial on B Cell Survival. Annual Review of Immunology, 2003, 21, 231-264.	9.5	874
5	BAFF-R, a Newly Identified TNF Receptor That Specifically Interacts with BAFF. Science, 2001, 293, 2108-2111.	6.0	827
6	Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA. Science, 2014, 343, 1221-1228.	6.0	774
7	Cloning and expression of human lipocortin, a phospholipase A2 inhibitor with potential anti-inflammatory activity. Nature, 1986, 320, 77-81.	13.7	684
8	Baff Mediates Survival of Peripheral Immature B Lymphocytes. Journal of Experimental Medicine, 2000, 192, 1453-1466.	4.2	625
9	BAFF: A fundamental survival factor for B cells. Nature Reviews Immunology, 2002, 2, 465-475.	10.6	619
10	TWEAK, a New Secreted Ligand in the Tumor Necrosis Factor Family That Weakly Induces Apoptosis. Journal of Biological Chemistry, 1997, 272, 32401-32410.	1.6	603
11	Distinct Roles in Lymphoid Organogenesis for Lymphotoxins Î± and Î² Revealed in Lymphotoxin Î²â€“Deficient Mice. Immunity, 1997, 6, 491-500.	6.6	564
12	Lymphotoxin Î±/Î² and Tumor Necrosis Factor Are Required for Stromal Cell Expression of Homing Chemokines in B and T Cell Areas of the Spleen. Journal of Experimental Medicine, 1999, 189, 403-412.	4.2	529
13	TAJ/TROY, an Orphan TNF Receptor Family Member, Binds Nogo-66 Receptor 1 and Regulates Axonal Regeneration. Neuron, 2005, 45, 353-359.	3.8	363
14	Baff Binds to the Tumor Necrosis Factor Receptorâ€“Like Molecule B Cell Maturation Antigen and Is Important for Maintaining the Peripheral B Cell Population. Journal of Experimental Medicine, 2000, 192, 129-136.	4.2	360
15	A Lymphotoxin-Driven Pathway to Hepatocellular Carcinoma. Cancer Cell, 2009, 16, 295-308.	7.7	345
16	Follicular Dendritic Cells Emerge from Ubiquitous Perivascular Precursors. Cell, 2012, 150, 194-206.	13.5	329
17	Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma. Nature Immunology, 2015, 16, 1235-1244.	7.0	278
18	Lymph Node Genesis Is Induced by Signaling through the Lymphotoxin Î² Receptor. Immunity, 1998, 9, 71-79.	6.6	266

#	Article	IF	Citations
19	TRAMP, a Novel Apoptosis-Mediating Receptor with Sequence Homology to Tumor Necrosis Factor Receptor 1 and Fas(Apo-1/CD95). Immunity, 1997, 6, 79-88.	6.6	265
20	Lymphotoxin/LIGHT, lymphoid microenvironments and autoimmune disease. Nature Reviews Immunology, 2003, 3, 642-655.	10.6	263
21	A Soluble Form of B Cell Maturation Antigen, a Receptor for the Tumor Necrosis Factor Family Member April, Inhibits Tumor Cell Growth. Journal of Experimental Medicine, 2000, 192, 1677-1684.	4.2	239
22	B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nature Reviews Drug Discovery, 2006, 5, 564-576.	21.5	239
23	Lymphotoxin-Î² Receptor Signaling Is Required for the Homeostatic Control of HEV Differentiation and Function. Immunity, 2005, 23, 539-550.	6.6	233
24	The Sequential Role of Lymphotoxin and B Cells in the Development of Splenic Follicles. Journal of Experimental Medicine, 1998, 187, 997-1007.	4.2	221
25	Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. Blood, 2012, 119, 1570-1580.	0.6	221
26	Mice overexpressing BAFF develop a commensal floraâ€“dependent, IgA-associated nephropathy. Journal of Clinical Investigation, 2011, 121, 3991-4002.	3.9	208
27	Regulation of TH2 development by CXCR5+ dendritic cells and lymphotoxin-expressing B cells. Nature Immunology, 2012, 13, 681-690.	7.0	187
28	Turning off follicular dendritic cells. Nature, 1998, 395, 26-27.	13.7	186
29	Lymphotoxin but not tumor necrosis factor functions to maintain splenic architecture and humoral responsiveness in adult mice. European Journal of Immunology, 1997, 27, 2033-2042.	1.6	180
30	Bilayers of phosphatidylserine: a deuterium and phosphorus nuclear magnetic resonance study. Biochemistry, 1980, 19, 1262-1270.	1.2	161
31	Both the lymphotoxin and tumor necrosis factor pathways are involved in experimental murine models of colitis. Gastroenterology, 1998, 115, 1464-1475.	0.6	145
32	The Requirement of Membrane Lymphotoxin for the Presence of Dendritic Cells in Lymphoid Tissues. Journal of Experimental Medicine, 1999, 190, 629-638.	4.2	140
33	A Role for the Lymphotoxin/LIGHT Axis in the Pathogenesis of Murine Collagen-Induced Arthritis. Journal of Immunology, 2003, 171, 115-126.	0.4	109
34	Blockade of lymphotoxin-beta receptor signaling reduces aspects of SjÃ¶gren syndrome in salivary glands of non-obese diabetic mice. Arthritis Research and Therapy, 2009, 11, R24.	1.6	107
35	Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTÎ²R. MAbs, 2009, 1, 128-141.	2.6	106
36	Expression of the lymphotoxin Î² receptor on follicular stromal cells in human lymphoid tissues. Cell Death and Differentiation, 1998, 5, 497-505.	5.0	100

#	Article	IF	Citations
37	Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile. Annals of the Rheumatic Diseases, 2020, 79, 379-386.	0.5	97
38	Targeting the Lymphotoxin-Î² Receptor with Agonist Antibodies as a Potential Cancer Therapy. Cancer Research, 2006, 66, 9617-9624.	0.4	95
39	A Longitudinal Biomarker for the Extent of Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis. Arthritis and Rheumatology, 2015, 67, 3004-3015.	2.9	95
40	Effect of mature lymphocytes and lymphotoxin on the development of the follicle-associated epithelium and M cells in mouse Peyer's patches. Gastroenterology, 2001, 120, 1173-1182.	0.6	90
41	Inhibition of the lymphotoxin pathway as a therapy for autoimmune disease. Immunological Reviews, 2008, 223, 202-220.	2.8	90
42	Elimination of Colonic Patches with Lymphotoxin Î² Receptor-Ig Prevents Th2 Cell-Type Colitis. Journal of Immunology, 2001, 167, 2781-2790.	0.4	86
43	Visualization of Lymphotoxin-Î² and Lymphotoxin-Î² Receptor Expression in Mouse Embryos. Journal of Immunology, 2002, 168, 5079-5087.	0.4	80
44	TRAF3 Controls Activation of the Canonical and Alternative NFÎºB by the Lymphotoxin Beta Receptor. Journal of Biological Chemistry, 2010, 285, 12971-12978.	1.6	75
45	Role of the Lymphotoxin/LIGHT System in the Development and Maintenance of Reticular Networks and Vasculature in Lymphoid Tissues. Frontiers in Immunology, 2014, 5, 47.	2.2	73
46	Lymphotoxin-beta receptor blockade reduces CXCL13 in lacrimal glands and improves corneal integrity in the NOD model of SjÃ¶gren's syndrome. Arthritis Research and Therapy, 2011, 13, R182.	1.6	71
47	Lymphotoxin Î² Receptor Triggering Induces Activation of the Nuclear Factor ÎºB Transcription Factor in Some Cell Types. Journal of Biological Chemistry, 1996, 271, 24934-24938.	1.6	63
48	Lung-resident memory B cells protect against bacterial pneumonia. Journal of Clinical Investigation, 2021, 131, .	3.9	62
49	Dimethyl Fumarate ameliorates pulmonary arterial hypertension and lung fibrosis by targeting multiple pathways. Scientific Reports, 2017, 7, 41605.	1.6	61
50	Reversal of virus-induced systemic shock and respiratory failure by blockade of the lymphotoxin pathway. Nature Medicine, 1999, 5, 1370-1374.	15.2	60
51	Clinical Efficacy and Safety of Baminercept, a Lymphotoxin Î² Receptor Fusion Protein, in Primary SjÃ¶gren's Syndrome. Arthritis and Rheumatology, 2018, 70, 1470-1480.	2.9	56
52	Essential Role of Lymph Nodes in Contact Hypersensitivity Revealed in Lymphotoxin-Î±â€“Deficient Mice. Journal of Experimental Medicine, 2001, 193, 1227-1238.	4.2	54
53	Monoclonal antibodies to lipocortin-1 as probes for biological function. FEBS Letters, 1990, 261, 247-252.	1.3	53
54	A role for surface lymphotoxin in experimental autoimmune encephalomyelitis independent of LIGHT. Journal of Clinical Investigation, 2003, 112, 755-767.	3.9	52

#	Article	IF	Citations
55	Manipulation of lymphoid microenvironments in nonhuman primates by an inhibitor of the lymphotoxin pathway. Journal of Clinical Investigation, 2002, 110, 1359-1369.	3.9	51
56	Motions and interactions of phospholipid head groups at the membrane surface. 3. Dynamic properties of amine-containing head groups. Biochemistry, 1981, 20, 7144-7151.	1.2	48
57	Altered Dermal Fibroblasts in Systemic Sclerosis Display Podoplanin and CD90. American Journal of Pathology, 2016, 186, 2650-2664.	1.9	48
58	Functional Effects of TNF and Lymphotoxin Î±1Î²2 on FDC-like Cells. Cellular Immunology, 2000, 203, 134-143.	1.4	45
59	Lymphotoxin Î² Receptor Signaling Promotes Development of Autoimmune Pancreatitis. Gastroenterology, 2012, 143, 1361-1374.	0.6	45
60	A role for lymphotoxin Î² receptor in host defense againstMycobacterium bovis BCG infection. European Journal of Immunology, 1999, 29, 4002-4010.	1.6	40
61	Lymphotoxin-LIGHT Pathway Regulates the Interferon Signature in Rheumatoid Arthritis. PLoS ONE, 2014, 9, e112545.	1.1	40
62	Interferons and rheumatoid arthritis: insight into interferon biology?. Trends in Immunology, 1987, 8, 372-374.	7.5	39
63	Dendritic cells maintain dermal adiposeâ€“derived stromal cells in skin fibrosis. Journal of Clinical Investigation, 2016, 126, 4331-4345.	3.9	38
64	Ca2+ influx across the excitable membrane of behavioural mutants of Paramecium. Nature, 1976, 259, 491-494.	13.7	35
65	Preparation and Characterization of Soluble Recombinant Heterotrimeric Complexes of Human Lymphotoxins and. Journal of Biological Chemistry, 1996, 271, 8618-8626.	1.6	35
66	Motions and interactions of phospholipid head groups at the membrane surface. 1. Simple alkyl head groups. Biochemistry, 1981, 20, 7123-7133.	1.2	33
67	Lymphotoxin Î² receptor signalling executesHelicobacter pylori-driven gastric inflammation in a T4SS-dependent manner. Gut, 2017, 66, 1369-1381.	6.1	33
68	The Lymphotoxin Network: Orchestrating a Type I interferon response to optimize adaptive immunity. Cytokine and Growth Factor Reviews, 2014, 25, 139-145.	3.2	29
69	Lymphotoxin Î² receptor mediates caspase-dependent tumor cell apoptosis in vitro and tumor suppression in vivo despite induction of NF-ÎºB activation. Carcinogenesis, 2013, 34, 1105-1114.	1.3	27
70	Manipulation of lymphoid microenvironments in nonhuman primates by an inhibitor of the lymphotoxin pathway. Journal of Clinical Investigation, 2002, 110, 1359-1369.	3.9	23
71	Perivascular Adventitial Fibroblast Specialization Accompanies T Cell Retention in the Inflamed Human Dermis. Journal of Immunology, 2019, 202, 56-68.	0.4	22
72	Motions and interactions of phospholipid head groups at the membrane surface. 2. Head groups with hydroxyl groups. Biochemistry, 1981, 20, 7133-7143.	1.2	16

#	Article	IF	Citations
73	The lymphotoxin Î² receptor is a potential therapeutic target in renal inflammation. Kidney International, 2016, 89, 113-126.	2.6	16
74	Extensive CD34-to-CD90 Fibroblast Transition Defines Regions of Cutaneous Reparative, Hypertrophic, and Keloidal Scarring. American Journal of Dermatopathology, 2019, 41, 16-28.	0.3	16
75	LTBR-Pathway in Sjogrenâ€™s Syndrome: CXCL13 Levels and B-cell-Enriched Ectopic Lymphoid Aggregates in NOD Mouse Lacrimal Glands Are Dependent on LTBR. Advances in Experimental Medicine and Biology, 2011, 691, 383-390.	0.8	11
76	Immunofibroblasts regulate LTÎ±3 expression in tertiary lymphoid structures in a pathway dependent on ICOS/ICOSL interaction. Communications Biology, 2022, 5, 413.	2.0	8
77	Pristane-Accelerated Autoimmune Disease in (SWR X NZB) F1 Mice Leads to Prominent Tubulointerstitial Inflammation and Human Lupus Nephritis-Like Fibrosis. PLoS ONE, 2016, 11, e0164423.	1.1	7
78	Amelioration of Murine Autoimmune Pancreatitis by Targeted LTÎ²R Inhibition and Anti-CD20 Treatment. ImmunoHorizons, 2020, 4, 688-700.	0.8	3
79	A Lymphotoxin-Driven Pathway to Hepatocellular Carcinoma. Cancer Cell, 2009, 16, 447.	7.7	1
80	Mice overexpressing BAFF develop a commensal floraâ€“dependent, IgA-associated nephropathy. Journal of Clinical Investigation, 2012, 122, 778-778.	3.9	1
81	JÃ¼rg Tschopp (1951â€“2011). Immunity, 2011, 34, 451-452.	6.6	0
82	Queenâ€™s Gambit: B Cell to Follicle. Journal of Immunology, 2021, 207, 753-754.	0.4	0
83	Title is missing!. , 0, 1, .		0
84	Workshop Summary: Control of Lymphocyte Function and Repertoire by the TNF Superfamily. Advances in Experimental Medicine and Biology, 2011, 691, 351-352.	0.8	0